Mileutis

Mileutis is a Bio-pharmaceutical company based in Israel south of Tel Aviv near the Weizmann Institute of Science focused on the discovery, development, and commercialization of novel biologically sourced, antibiotic free, safe, and residue free therapies. Mileutis’ mission is the development of Bio-pharmaceutical products to create a healthier world where antibiotics, and hormones are largely replaced with residue free and safe Human and Animal Healthcare products to significantly reduce the global threat of Anti-Microbial Resistance (AMR) from the overuse of antibiotics.

Mileutis technology portfolio includes 5 granted patents in the US, and 62 granted patents worldwide.

Mileutis, with its safe, and residue free small milk derived protein based (peptides) products designed to improve both animal and human health while reducing antibiotic use, is proud to be a part of the solution to addressing AMR. AMR is largely caused by the overuse of antimicrobial medicines with 70% coming from the animal healthcare sector.

Mileutis’ initial focus is on the Dairy Industry segment of the Animal Healthcare market, in which its leading products can reduce up to 90% of currently administered antibiotic treatments to dairy cows. Dairy farmers lack a safe and effective way to manage Mastitis which is the #1 problem facing the Dairy industry affecting over 30% of cows worldwide. It is an infectious disease resulting in inflammation in the mammary gland of the cow. This is the primary cause of milk production loss and overuse of antibiotics to try and treat or prevent the disease, often unsuccessfully, resulting in economic losses exceeding $30 billion globally per year.

Today, there are no FDA-approved, non-antibiotic, nongenetically modified (GMO), intramammary treatments for the management of mastitis. Mileutis is solving this problem with its Next Generation biologically sourced, safe, and residual free Bio-pharmaceuticals, Imilac™, administered at the beginning of the Dry-Off period and Milac™, administered during lactation. These natural and innovative novel treatments act through an immune-modulatory effect enabling the management of infectious and chronic diseases without the use of antibiotics revolutionizing the way veterinarians treat and manage mastitis. The European Medicines Agency (EMA) published a positive opinion on the safety of Mileutis products by confirming that no Maximum Residue Level (MRL) evaluation is required for Mileutis’ technology.

In addition to addressing the global challenge of AMR, Mileutis’ products have many benefits for the farmers, consumers, the environment, and the dairy cows themselves. Consumers will receive a product free of antimicrobials and hormones; the farmer benefits from advanced technology that increases milk production per cow for added revenues, while reducing wasted milk, nutrient input and waste output per unit for cost savings; and the cow’s wellbeing is improved by a faster dry off (involution) period and a more efficacious treatment of mastitis in severe cases. The product is easy to use for the farmers and has a clear safety profile. With increased output per cow, fewer cows will be needed to produce the same amount of milk. Benefits to the environment include reduced GHG (Greenhouse Gas) emissions and increased availability of arable land for food and other crops as less land will be needed for grazing.

The company is preparing for the final regulatory track and launch of its leading line of products in selected markets.